Resonetics Forges Bioelectronics Hub with Key Med-Ally Acquisition

NASHUA, NH – January 06, 2026 – Resonetics has executed a strategic acquisition that significantly enhances its position in the advanced medical device market, purchasing the manufacturing assets, process know-how, and intellectual property for implantable pulse generators (IPGs) from Med-Ally. The move signals a major expansion of Resonetics' Medical Power business, transforming the company from a key component supplier into an integrated solutions provider for the next generation of active implantable devices.

This acquisition allows Resonetics to pair its established expertise in implantable battery technologies with the complex manufacturing of the pulse generators that control them. By consolidating these critical elements, the company aims to offer a more streamlined and efficient development pathway for medical device original equipment manufacturers (OEMs) in the rapidly growing neuromodulation, brain-computer-interface (BCI), and cardiac rhythm management (CRM) sectors. The acquired assets and technology, developed by the Charleston-based Med-Ally, will be integrated into an existing Resonetics facility, solidifying the company's capabilities under one operational umbrella.

Building a 'One-Stop Shop' for Bioelectronics

The deal represents a deliberate shift in strategy, moving Resonetics up the value chain to provide a more comprehensive package for bioelectronic device developers. Previously known for its pioneering work in laser processing and nitinol manufacturing, the company is now positioned to deliver the core electronic systems for active implants, from the energy source to the therapeutic output.

Med-Ally, founded in 2011, carved out a niche by focusing on the complex needs of the bioelectronic and neuromodulation markets. The company's expertise is embodied in its VersaStim® neuromodulation technology platforms—programmable and adaptable systems designed to accelerate development for therapies targeting chronic pain, Parkinson's disease, epilepsy, and other neurological conditions. The acquisition includes this valuable IP and the specialized manufacturing infrastructure Med-Ally built, including a Class 7 cleanroom equipped for hermetic enclosure welding and fine-pitch laser processing.

This vertical integration is a direct response to market demand. "This acquisition represents an important step forward for our Bioelectronic market segment," said Kevin Kelly, CEO of Resonetics. "We already provide implantable batteries that power neurostimulation and cardiac devices. Now we can manufacture the pulse generators themselves, giving customers a more integrated and efficient solution."

By offering both the battery and the IPG, Resonetics can help its customers de-risk their supply chains, reduce development timelines, and ensure seamless integration between two of the most critical components of an active implantable device. This synergy is expected to be a powerful differentiator in a competitive landscape.

"Combining IPG manufacturing & assembly with Resonetics' implantable battery expertise creates a differentiated capability in the industry," added Fred Borne, VP of Fiber Optic Sensors & Medical Power at Resonetics. "We're now positioned to be the comprehensive partner for next-generation neuromodulation devices, something our customers have been seeking."

Powering the Next Wave of Medical Innovation

The timing of the acquisition aligns perfectly with the explosive growth projected for the markets Resonetics is targeting. These sectors are fueled by an aging global population, the rising prevalence of chronic conditions, and continuous technological breakthroughs.

The global neuromodulation market, valued at over $9 billion in 2025, is forecast to surge to more than $25 billion by 2034, expanding at a compound annual growth rate (CAGR) of over 12%. This growth is driven by the increasing adoption of therapies for neurological disorders that were previously difficult to manage.

Similarly, the brain-computer interface market is on a steep upward trajectory. The U.S. BCI market alone is projected to grow from approximately $700 million in 2026 to over $2.7 billion by 2034, reflecting a staggering CAGR of nearly 18%. As researchers make strides in treating paralysis and neurodegenerative disorders, the demand for sophisticated, reliable implantable hardware is escalating.

Even the more established cardiac rhythm management market continues its robust expansion, with estimates projecting it to grow from around $30 billion in 2025 to nearly $50 billion by 2033. Innovations in device longevity, size reduction, and connectivity are key drivers, all of which depend on advanced power and control electronics. By integrating IPG manufacturing, Resonetics is directly addressing the core technological needs of these dynamic, high-value markets.

The Private Equity Blueprint for a MedTech Powerhouse

This acquisition is not an isolated event but the latest move in a calculated and aggressive growth strategy orchestrated by Resonetics' private equity backers, Carlyle and GTCR. The firms are executing a clear plan to build Resonetics into a dominant force in specialized medical device manufacturing through strategic acquisitions that add niche, high-value capabilities.

This is the third significant transaction for Resonetics in the last twelve months. In May 2025, the company acquired the nitinol gun drilling operations from Medical Component Specialists. This move secured in-house control over a critical process for manufacturing with nitinol, a 'super-elastic' metal alloy essential for many next-generation implants and delivery systems. Just a few months later, in September 2025, Resonetics acquired Eden Holdings, a specialist in precision injection molding and micro-machining. That deal significantly expanded the company's polymer processing capabilities, crucial for components in robotic surgery and electrophysiology devices.

Viewed together, these three acquisitions—covering advanced metal processing, precision polymers, and now, integrated bioelectronics—reveal a cohesive blueprint. Carlyle and GTCR are assembling a uniquely versatile contract development and manufacturing organization (CDMO) capable of handling the most complex and innovative medical device challenges from multiple angles. The strategy is to create a market leader not just through scale, but through an unparalleled breadth of highly specialized, complementary technologies.

By adding Med-Ally's pulse generator expertise, Resonetics solidifies its role as a critical enabler for medtech innovators. It can now support device development from raw material and micro-fabrication all the way to the active electronic heart of an implantable device. This comprehensive capability set redefines its competitive position, making it a formidable partner for any company looking to push the boundaries of medical technology.